panulisib
- Generic Name
- panulisib
Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors
- First Posted Date
- 2013-01-07
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Piramal Enterprises Limited
- Target Recruit Count
- 60
- Registration Number
- NCT01762410
- Locations
- 🇮🇳
Medanta Duke Research Institute (MDRI), Gurgaon, Haryana, India
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇮🇳Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath